ENTRY       D10159            Mixture   Drug
NAME        Alogliptin benzoate and pioglitazone hydrochloride;
            Liovel (TN);
            Oseni (TN);
            Incresync (TN)
PRODUCT     OSENI (Takeda Pharmaceuticals America)
  GENERIC   ALOGLIPTIN AND PIOGLITAZONE (Padagis Israel Pharmaceuticals)
COMPONENT   Alogliptin benzoate [DR:D06553], Pioglitazone hydrochloride [DR:D00945]
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
REMARK      Therapeutic category: 3969
            ATC code: A10BD09
            Product: D10159<JP/US>
EFFICACY    Antidiabetic
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BD Combinations of oral blood glucose lowering drugs
                 A10BD09 Pioglitazone and alogliptin
                  D10159  Alogliptin benzoate and pioglitazone hydrochloride &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Combinations
               Alogliptin Benzoate/ Pioglitazone Hydrochloride
                D10159  Alogliptin benzoate and pioglitazone hydrochloride
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D10159  Alogliptin benzoate and pioglitazone hydrochloride
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D10159  Alogliptin benzoate and pioglitazone hydrochloride
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D10159  Alogliptin benzoate and pioglitazone hydrochloride
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10159
DBLINKS     PubChem: 135626877
///
